<DOC>
	<DOCNO>NCT02103062</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Abraxane ( nab-paclitaxel ) subject previously treat metastatic colorectal cancer . Subjects place two separate cohort base RAS mutation status .</brief_summary>
	<brief_title>Phase 2 Study With Abraxane ( Nab®Paclitaxel ) Metastatic Colorectal Cancer</brief_title>
	<detailed_description>ABI-007-COLO-001 Phase 2 , single arm , open label , multicenter study evaluate efficacy safety Abraxane ( nab-paclitaxel ) give day 1 , 8 15 28 day cycle subject previously treat metastatic colorectal cancer . Subjects enrol cohort RAS mutation status ( wildtype mutate ) . Stage 1 give cohort enroll 15 subject Intention Treat population 8 subject Progression Free Survival 8 week assessment , Stage 2 open respective cohort . Stage 2 enroll additional 28 subject total 43 subject cohort . The study positive 26 subject Progression Free Survival 8 week assessment observe 43 subject per cohort . Interim analysis Stage 1 meet protocol define criterion proceed Stage 2 . Patients currently enrol follow Progression Free Survival 28 day last dose , secondary endpoint include overall survival follow</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1 . Subject ≥ 18 year old time signing Informed Consent Form 2 . Subject histological cytological diagnosis adenocarcinoma colon rectum , evidence metastasis 3 . Subject know KRAS mutation status ( mutate wildtype ) . NRAS mutation status may unknown . 4 . Subject documented disease progression ≤ 2 month last administration last standard therapy . . Subjects treat oxaliplatin adjuvant setting , progress within 6 month completion adjuvant therapy 5 . Subject either received prior treatment candidate prior treatment , fluoropyrimidine , oxaliplatin , irinotecan antiVEGF therapy ( e.g . bevacizumab zivaflibercept ) ; RAS wildtype tumor , antiEGFR therapy ( e.g . cetuximab panitumumab ) . 6 . Subject Eastern Cooperative Oncology Group performance status 0 1 7 . Subject radiographicallydocumented measurable disease , per Response Evaluation Criteria Solid Tumors version 1.1 criterion 8 . Subject adequate organ function , evidence following : 1 . Aspartate Aminotransferase ( SGOT ) , Alanine Transaminase ( SGPT ) ≤ 2.5 × upper limit normal range , &lt; 5 x upper limit normal range liver metastasis present 2 . Total bilirubin ≤ 1.5 × upper limit normal range 3 . Creatinine ≤ 1.5 × upper limit normal range 9 . Subject adequate bone marrow function , evidence following : 1 . Absolute neutrophil count ≥ 1.5 × 109 cells/millimeters3 2 . Platelets ≥ 100 × 109 cells/millimeters3 ( transfusion independent , define receive platelet transfusion within 7 day prior laboratory sample ) 3 . Hemoglobin ≥ 9 grams/decilitre ( transfusion permit fulfill criterion ) 10 . Females childbearing potential ( define sexually mature woman ( 1 ) undergone hysterectomy [ surgical removal uterus ] bilateral oophorectomy [ surgical removal ovary ] ( 2 ) naturally postmenopausal least 24 consecutive month [ i.e. , menses time precede 24 consecutive month ] ) must : 1 . Either commit true abstinence* heterosexual contact ( must review monthly basis ) , agree use , able comply , effective contraception without interruption , 28 day prior start Investigational Product therapy ( include dose interruption ) , 3 month follow last dose Investigational Product ; 2 . Have negative serum pregnancy test ( β human Chorionic Gonadotrophin ) result screen agree ongoing pregnancy test course study , end study therapy . This apply even subject practice true abstinence* heterosexual contact . * True abstinence acceptable line prefer usual lifestyle subject . Note : Periodic abstinence ( e.g , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . 11 . Male subject must practice true abstinence* agree use condom sexual contact pregnant female female childbearing potential participating study , dose interruption 6 month follow Investigational Product discontinuation , even undergone successful vasectomy . 12 . Subject must understand voluntarily sign Informed Consent Form prior study related assessment procedure conduct . 13 . Subject must able adhere study visit schedule protocol requirement . 1 . Subject current history brain metastasis . In subject symptomatic , brain scan require exclude metastasis . 2 . Subject ≥ National Cancer Institute Common Terminology Criteria Adverse Events grade 2 peripheral neuropathy screen 3 . Subject prior treatment regorafenib 4 . Subject receive radiotherapy ≤ 4 week limited field radiation palliation ≤ 2 week prior start Investigational Product , and/or ≥ 30 % bone marrow irradiate . Radiation therapy target lesion permit clear progression lesion since radiation complete . 5 . Subject major surgery within 14 day prior start Investigational Product recover postoperative complication 6 . Subject recover acute toxic effect prior anticancer therapy , radiation major /significant trauma 7 . Subject history allergy hypersensitivity nabpaclitaxel excipients 8 . Subject known history follow within 6 month prior enrollment ( decision include subject study ) : myocardial infarction , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , New York Heart Association Class IIIIV heart failure , uncontrolled hypertension , clinically significant cardiac dysrhythmia Electrocardiogram abnormality , cerebrovascular accident , transient ischemic attack , seizure disorder 9 . Subject know infection hepatitis B C , history human immunodeficiency virus infection , subject receive immunosuppressive myelosuppressive medication would opinion investigator , increase risk serious neutropenic complication 10 . Subject active , uncontrolled bacterial , viral , fungal infection ( ) require systemic therapy , define ongoing signs/symptoms related infection without improvement despite appropriate antibiotic , antiviral therapy , and/or treatment 11 . Subject malignancy within 5 year prior enrolment , exception adequately treat insitu carcinoma cervix , uteri , nonmelanomatous skin cancer ( treatment complete 6 month prior enrollment ) 12 . Subject history connective tissue disorder ( eg , lupus , scleroderma , arteritis nodosa ) 13 . Subject history interstitial lung disease , history slowly progressive dyspnea unproductive cough , sarcoidosis , silicosis , idiopathic pulmonary fibrosis , pulmonary hypersensitivity pneumonitis multiple allergy 14 . Subject concurrent severe and/or uncontrolled medical condition would , investigator 's judgment , contraindicate subject participation clinical study ( e.g . chronic pancreatitis , chronic active hepatitis , etc . ) 15 . Subject enrol clinical protocol investigational study interventional agent assessment may interfere study procedure 16 . Subject significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study 17 . Subject condition confounds ability interpret data study 18 . Subject unwilling unable comply study procedures 19 . Subject pregnant nursing female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>nab®Paclitaxel</keyword>
	<keyword>Response Evaluation Solid Tumors</keyword>
	<keyword>Progression Free Survival</keyword>
	<keyword>Overall Survival</keyword>
	<keyword>Duration Response</keyword>
	<keyword>RAS</keyword>
</DOC>